Close Menu

NEW YORK – Thermo Fisher Scientific said on Tuesday that the US Food and Drug Administration has granted premarket approval for its Oncomine Dx Target Test as a companion diagnostic for pralsetinib (Gavreto), a targeted drug developed by Blueprint Medicines, to identify RET fusions in metastatic non-small cell lung cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The European Medicines Agency recommends that a warning about the possibility of blood clots be added to the product information.

According to Agence France Presse, astronauts who are to arrive soon at the International Space Station are to study the effect of microgravity on brain organoids and more.

A new study finds that farmed fish have led to a decline in genetic diversity among Atlantic salmon, the Guardian reports.

In Cell this week: analysis of SARS-CoV-2 B.1.1.7 introductions to the US, increased horizontal gene transfer higher in gut microbiomes linked to industrialization, and more.

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.